Clinical trial · Interventional
A Clinical Study of Pain and Discomfort Associated With Advanced Lung Cancer
A Clinical Study of 35 kDa Hyaluronan Fragment in Treatment of Pain and Discomfort Associated With Advanced Lung Cancer
NCT05852002CI-TRIAL-00073050completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this research, the patients with advanced lung cancer accompanied by pain and discomfort were treated by injecting freshly manufactured tissue permeable hyaluronan fragment HA35 into the tissue under abdominal adipose.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Lung Cancer | Malignant Lung Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 35 kDa hyaluronan fragment | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 35 kDa hyaluronan fragment injection
- description
- 35kDa hyaluronan fragment was produced by using hyaluronidase PH20 to cleave 1600kDa hyaluronan ( HA1600 ). Batch number of 35 kDa hyaluronan fragment injection is L20200708MP07707,and the injection was approved by Ministry of Health, Mongolia.
- interventionNames
- Drug: 35 kDa hyaluronan fragment
Primary outcomes (5)
- measure
- A pain scale
- timeFrame
- twenty eight days
- description
- 0 represents no pain or discomfort , while 10 represents the most serious pain or discomfort.
- measure
- Respiratory symptom cough
- timeFrame
- twenty eight days
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Age\>=18 years old * Sign the informed consent form voluntarily. * Expected survival ≥3 months. * Pathologically confirmed locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC), which is currently not suitable for local treatment such as radical surgery or radiotherapy. * The subject has good compliance and cooperates with the follow-up. Exclusion Criteria: * Subjects who are receiving systematic steroid treatments before the first cell treatment. * Subjects with a history of mental disorders or drug abuse that may influence treatment compliance. * Women in pregnancy or lactation or are expected to be pregnant during the study.
References
Publications (0)
Data not yet available
No reference posted for this study.